FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601144035> ?p ?o ?g. }

• W2601144035 abstract "ABSTRACT Relebactam (formerly MK-7655) is an inhibitor of class A and C β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC), and is currently in clinical development in combination with imipenem-cilastatin. Using Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution methodology, we evaluated the in vitro activities of imipenem-relebactam, imipenem, and seven routinely tested parenteral antimicrobial agents against Gram-negative ESKAPE pathogens (including Klebsiella pneumoniae , n = 689; Acinetobacter baumannii , n = 72; Pseudomonas aeruginosa , n = 845; and Enterobacter spp., n = 399) submitted by 21 clinical laboratories in the United States in 2015 as part of the SMART (Study for Monitoring Antimicrobial Resistance Trends) global surveillance program. Relebactam was tested at a fixed concentration of 4 μg/ml in combination with doubling dilutions of imipenem. Imipenem-relebactam MICs were interpreted using CLSI imipenem breakpoints. The respective rates of susceptibility to imipenem-relebactam and imipenem were 94.2% (796/845) and 70.3% (594/845) for P. aeruginosa , 99.0% (682/689) and 96.1% (662/689) for K. pneumoniae , and 100% (399/399) and 98.0% (391/399) for Enterobacter spp. Relebactam restored imipenem susceptibility to 80.5% (202/251), 74.1% (20/27), and 100% (8/8) of isolates of imipenem-nonsusceptible P. aeruginosa , K. pneumoniae , and Enterobacter spp. Relebactam did not increase the number of isolates of Acinetobacter spp. susceptible to imipenem, and the rates of resistance to all of the agents tested against this pathogen were >30%. Further development of imipenem-relebactam is warranted given the demonstrated ability of relebactam to restore the activity of imipenem against current clinical isolates of Enterobacteriaceae and P. aeruginosa that are nonsusceptible to carbapenems and its potential as a therapy for treating patients with antimicrobial-resistant Gram-negative infections." @default.
• W2601144035 created "2017-04-07" @default.
• W2601144035 creator A5017159626 @default.
• W2601144035 creator A5038009031 @default.
• W2601144035 creator A5042149117 @default.
• W2601144035 creator A5061522332 @default.
• W2601144035 creator A5062847775 @default.
• W2601144035 creator A5066677972 @default.
• W2601144035 creator A5089366807 @default.
• W2601144035 date "2017-06-01" @default.
• W2601144035 modified "2023-10-17" @default.
• W2601144035 title "<i>In Vitro</i> Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)" @default.
• W2601144035 cites W1963880769 @default.
• W2601144035 cites W1983774126 @default.
• W2601144035 cites W2043982549 @default.
• W2601144035 cites W2059728033 @default.
• W2601144035 cites W2092279762 @default.
• W2601144035 cites W2099303284 @default.
• W2601144035 cites W2103121782 @default.
• W2601144035 cites W2103137511 @default.
• W2601144035 cites W2106204528 @default.
• W2601144035 cites W2110880963 @default.
• W2601144035 cites W2115486016 @default.
• W2601144035 cites W2116644484 @default.
• W2601144035 cites W2123978275 @default.
• W2601144035 cites W2129326896 @default.
• W2601144035 cites W2129772896 @default.
• W2601144035 cites W2134789996 @default.
• W2601144035 cites W2139911027 @default.
• W2601144035 cites W2168519960 @default.
• W2601144035 cites W2171104727 @default.
• W2601144035 cites W2201379139 @default.
• W2601144035 cites W2288514582 @default.
• W2601144035 cites W2408072278 @default.
• W2601144035 doi "https://doi.org/10.1128/aac.02209-16" @default.
• W2601144035 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5444184" @default.
• W2601144035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28320716" @default.
• W2601144035 hasPublicationYear "2017" @default.
• W2601144035 type Work @default.
• W2601144035 sameAs 2601144035 @default.
• W2601144035 citedByCount "105" @default.
• W2601144035 countsByYear W26011440352017 @default.
• W2601144035 countsByYear W26011440352018 @default.
• W2601144035 countsByYear W26011440352019 @default.
• W2601144035 countsByYear W26011440352020 @default.
• W2601144035 countsByYear W26011440352021 @default.
• W2601144035 countsByYear W26011440352022 @default.
• W2601144035 countsByYear W26011440352023 @default.
• W2601144035 crossrefType "journal-article" @default.
• W2601144035 hasAuthorship W2601144035A5017159626 @default.
• W2601144035 hasAuthorship W2601144035A5038009031 @default.
• W2601144035 hasAuthorship W2601144035A5042149117 @default.
• W2601144035 hasAuthorship W2601144035A5061522332 @default.
• W2601144035 hasAuthorship W2601144035A5062847775 @default.
• W2601144035 hasAuthorship W2601144035A5066677972 @default.
• W2601144035 hasAuthorship W2601144035A5089366807 @default.
• W2601144035 hasBestOaLocation W26011440351 @default.
• W2601144035 hasConcept C104317684 @default.
• W2601144035 hasConcept C176947019 @default.
• W2601144035 hasConcept C2776315533 @default.
• W2601144035 hasConcept C2776685102 @default.
• W2601144035 hasConcept C2777058267 @default.
• W2601144035 hasConcept C2777637488 @default.
• W2601144035 hasConcept C2778523567 @default.
• W2601144035 hasConcept C2778983983 @default.
• W2601144035 hasConcept C2779631663 @default.
• W2601144035 hasConcept C2780950330 @default.
• W2601144035 hasConcept C4937899 @default.
• W2601144035 hasConcept C501593827 @default.
• W2601144035 hasConcept C523546767 @default.
• W2601144035 hasConcept C54355233 @default.
• W2601144035 hasConcept C547475151 @default.
• W2601144035 hasConcept C55493867 @default.
• W2601144035 hasConcept C71924100 @default.
• W2601144035 hasConcept C86803240 @default.
• W2601144035 hasConcept C89423630 @default.
• W2601144035 hasConcept C94665300 @default.
• W2601144035 hasConceptScore W2601144035C104317684 @default.
• W2601144035 hasConceptScore W2601144035C176947019 @default.
• W2601144035 hasConceptScore W2601144035C2776315533 @default.
• W2601144035 hasConceptScore W2601144035C2776685102 @default.
• W2601144035 hasConceptScore W2601144035C2777058267 @default.
• W2601144035 hasConceptScore W2601144035C2777637488 @default.
• W2601144035 hasConceptScore W2601144035C2778523567 @default.
• W2601144035 hasConceptScore W2601144035C2778983983 @default.
• W2601144035 hasConceptScore W2601144035C2779631663 @default.
• W2601144035 hasConceptScore W2601144035C2780950330 @default.
• W2601144035 hasConceptScore W2601144035C4937899 @default.
• W2601144035 hasConceptScore W2601144035C501593827 @default.
• W2601144035 hasConceptScore W2601144035C523546767 @default.
• W2601144035 hasConceptScore W2601144035C54355233 @default.
• W2601144035 hasConceptScore W2601144035C547475151 @default.
• W2601144035 hasConceptScore W2601144035C55493867 @default.
• W2601144035 hasConceptScore W2601144035C71924100 @default.
• W2601144035 hasConceptScore W2601144035C86803240 @default.
• W2601144035 hasConceptScore W2601144035C89423630 @default.
• W2601144035 hasConceptScore W2601144035C94665300 @default.
• W2601144035 hasFunder F4320307776 @default.
• W2601144035 hasIssue "6" @default.
• W2601144035 hasLocation W26011440351 @default.

• next